Literature DB >> 3782761

Serum cholinesterase in patients with fatty liver.

F Nomura, K Ohnishi, H Koen, Y Hiyama, T Nakayama, Y Itoh, K Shirai, Y Saitoh, K Okuda.   

Abstract

In search of a practical biochemical test that will reflect hepatic steatosis, we assessed the significance of serum cholinesterase activity in 48 patients with nonalcoholic fatty liver, 16 obese subjects without fatty liver, 30 cases of chronic persistent hepatitis, 38 cases of chronic active hepatitis, and 20 cases of liver cirrhosis. Increased cholinesterase activity was observed in nonobese as well as obese patients with fatty liver, whereas obese subjects without fatty liver showed levels in the upper normal range. When we set a cutoff level above the upper normal limit, half of the patients with fatty liver showed values above it, with only a few overlaps with other patients. When obese patients with fatty liver took a low-caloric diet, cholinesterase activity decreased, clearly reflecting improvement of hepatic steatosis. Thus, measurement of cholinesterase activity is of diagnostic value and an alternative to computed tomography in hepatic steatosis, and will provide a practical measure for the assessment of effects during follow-up.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782761     DOI: 10.1097/00004836-198610000-00025

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  6 in total

1.  Hepatocyte-specific depletion of ubiquitin regulatory X domain containing protein 8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model.

Authors:  Norihiro Imai; Michitaka Suzuki; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Kazuhiko Hayashi; Masatoshi Ishigami; Yoshiki Hirooka; Tetsuya Ishikawa; Hidemi Goto; Toyoshi Fujimoto
Journal:  Histochem Cell Biol       Date:  2017-04-18       Impact factor: 4.304

2.  [Assessment of nutritional status--a part of routine clinical diagnosis: cholinesterase activity as a nutritional indicator].

Authors:  G Ollenschläger; M Schrappe-Bächer; M Steffen; B Bürger; B Allolio
Journal:  Klin Wochenschr       Date:  1989-11-03

3.  Butyrylcholinesterase level as an independent factor of erythropoiesis-stimulating agent resistance in patients on maintenance hemodialysis: a single-center cross-sectional study.

Authors:  Teppei Okamoto; Shingo Hatakeyama; Yoshimi Tanaka; Kengo Imanishi; Tooru Takashima; Fumitada Saitoh; Takuya Koie; Tadashi Suzuki; Chikara Ohyama
Journal:  Clin Exp Nephrol       Date:  2018-03-29       Impact factor: 2.801

4.  A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid.

Authors:  Natalia Lampon; J Carlos Tutor
Journal:  Ups J Med Sci       Date:  2010-12-29       Impact factor: 2.384

5.  Plasma cholinesterase is associated with Chinese adolescent overweight or obesity and metabolic syndrome prediction.

Authors:  Yanshuo Han; Yanan Ma; Yang Liu; Zhongyi Zhao; Shihan Zhen; Xuelian Yang; Zhiyong Xu; Deliang Wen
Journal:  Diabetes Metab Syndr Obes       Date:  2019-05-14       Impact factor: 3.168

6.  Butyrylcholinesterase as a prognostic marker: a review of the literature.

Authors:  Lidia Santarpia; Ilenia Grandone; Franco Contaldo; Fabrizio Pasanisi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-09-06       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.